Investigational drug · Phase 3
MRG002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic Urothelium Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 13, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "MRG002"
First trial start
2023
Apr 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MRG002", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Advanced or Metastatic Urothelium Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MRG002" as an intervention, largest first.
- A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast CancerPivotal-lookingStatus unknown
Shanghai Miracogen Inc.Industry
NCT04924699 · 350 participants (planned) · Start Jun 30, 2021 · Primary completion Sep 2023
Drug: MRG002; Trastuzumab Emtansine for Injection · For: Advanced Breast Cancer; Metastatic Breast Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 19 sites in all
- A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial CancerPivotal-lookingRecruiting
Shanghai Miracogen Inc.Industry
NCT05754853 · 290 participants (planned) · Start Apr 6, 2023 · Primary completion Oct 2025
Drug: MRG002; Docetaxel Injection and 3 more · For: Advanced or Metastatic Urothelium Cancer
Sites: Beijing, China
Shanghai Miracogen Inc.Industry
NCT04492488 · 129 participants (planned) · Start May 24, 2021 · Primary completion Oct 18, 2022
Drug: MRG002 · For: Advanced Solid Tumors; Advanced or Metastatic Gastric Cancer; Advanced or Metastatic Gastroesophageal Junction Cancer
Sites: Orange, California; Houston, Texas
- A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).Status unknown
Shanghai Miracogen Inc.Industry
NCT05141786 · 100 participants (planned) · Start Dec 2021 · Primary completion Dec 2023
Drug: MRG002 · For: Non-small- Cell Lung Cancer (NSCLC)
Sites: Shanghai, China
Shanghai Miracogen Inc.Industry
NCT05263869 · 99 participants (planned) · Start Mar 23, 2022 · Primary completion Dec 2022
Drug: MRG002 · For: Breast Cancer With Liver Metastases
Sites: Beijing, China; Guangzhou, China
- A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract CancerStatus unknown
Shanghai Miracogen Inc.Industry
NCT04837508 · 86 participants (planned) · Start Jun 7, 2021 · Primary completion Dec 2022
Drug: MRG002 · For: Advanced or Metastatic Biliary Tract Cancer
Sites: Bengbu, China; Beijing, China; Guangzhou, China · 7 sites in all
- A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid TumorsStatus unknown
Shanghai Miracogen Inc.Industry
NCT04941339 · 74 participants (planned) · Start Nov 21, 2018 · Primary completion Oct 2022
Drug: MRG002 · For: Advanced Solid Tumor
Sites: Shanghai, China
- A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)Status unknown
Shanghai Miracogen Inc.Industry
NCT04742153 · 66 participants (planned) · Start May 13, 2021 · Primary completion Feb 2023
Drug: MRG002 · For: Advanced or Metastatic Breast Cancer
Sites: Beijing, China; Shijiazhuang, China
Shanghai Miracogen Inc.Industry
NCT05141747 · 60 participants (planned) · Start Jan 19, 2022 · Primary completion Dec 2023
Drug: MRG002 · For: Locally Advanced Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer
Sites: Beijing, China; Changsha, China; Shanghai, China
- A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium CancerStatus unknown
Shanghai Miracogen Inc.Industry
NCT04839510 · 58 participants (planned) · Start Apr 20, 2021 · Primary completion Jun 2022
Drug: MRG002 · For: Locally Advanced Urothelial Cancer; Metastatic Urothelial Carcinoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- HER2-Targeted Antibody-Drug Conjugates in Advanced HER2-Low Breast Cancer: Mechanisms, Clinical Efficacy, and Resistance Strategies.
Yang M, Ding X, Ye P, et al. · Cancer Manag Res 2026
- Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform.
Dang X, Zhang C, Shang J, et al. · Angew Chem Int Ed Engl 2026
- Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial.
Zhang S, Sun T, Wang X, et al. · Eur J Cancer 2025
- Antibody-drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis.
Michelon I, Dacoregio MI, Vilbert M, et al. · Ther Adv Med Oncol 2024
- A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma.
Qu W, Fu C, Han W, et al. · Eur J Cancer 2024
- Antibodies to watch in 2024.
Crescioli S, Kaplon H, Chenoweth A, et al. · MAbs 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.